Welcome to the international HTA database

Showing [24038 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2011	NIHR Health Technology Assessment programme	Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Functional Electrical Stimulation (FES) for children with spinal cord injuries: a review of the clinical effectiveness and guidelines
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Paliperidone palmitate (Xeplion®)
2011	NIHR Health Technology Assessment programme	The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation
2011	NIHR Health Technology Assessment programme	Ranibizumab for the treatment of macular oedema caused by retinal vein occlusion (RVO): a single technology appraisal
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Glyburide, gliclazide or glimepiride in the elderly with type 2 diabetes: a review of the clinical effectiveness and safety
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Dasatinib (Sprycel®)
2011	NIHR Health Technology Assessment programme	EVerT: cryotherapy versus salicylic acid for the treatment of verrucae - a randomised controlled trial
2011	NIHR Health Technology Assessment programme	Trabectedin for the treatment of relapsed ovarian cancer
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Fluticasone furoate versus fluticasone propionate for seasonal allergic rhinitis: a review of the clinical and cost-effectiveness
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Tapentadol prolonged release (Palexia® SR)
2011	NIHR Health Technology Assessment programme	Accuracy of bacterial DNA testing for central venous catheter-associated bloodstream infection in children with cancer
2011	NIHR Health Technology Assessment programme	Roflumilast for the management of severe chronic obstructive pulmonary disease
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Antiplatelet agents for acute coronary syndrome: a review of the guidelines and recommendations
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Alteplase (Actilyse® Cathflo® 2 mg)
2011	NIHR Health Technology Assessment programme	Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation
2011	NIHR Health Technology Assessment programme	Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Calibration of blood glucose monitors for diabetes: a review of the clinical evidence and guidelines
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Saxagliptin (Onglyza®)
2011	NIHR Health Technology Assessment programme	Hysterectomy, endometrial ablation and Mirena for heavy menstrual bleeding: a systematic review of clinical effectiveness and costeffectiveness analysis
2011	NIHR Health Technology Assessment programme	Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Venous thromboembolism prophylaxis for major general surgery: a review of the clinical effectiveness and guidelines
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Bevacizumab (Avastin) for triple negative adjuvant breast cancer; in combination with taxane and/or anthracycline chemotherapy
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Sodium valproate (Episenta®)
2011	NIHR Health Technology Assessment programme	The clinical effectiveness and safety of prophylactic retinal interventions to reduce the risk of retinal detachment and subsequent vision loss in adults and children with Stickler syndrome: a systematic review
2011	NIHR Health Technology Assessment programme	A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Amisulpride for adults with refractory schizophrenia: a review of the clinical effectiveness and safety
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Collagenase Clostridium histolyticum (Xiapex®)
2011	NIHR Health Technology Assessment programme	MAVARIC - a comparison of automation-assisted and manual cervical screening: a randomised controlled trial
2011	NIHR Health Technology Assessment programme	Prucalopride for the treatment of chronic constipation in women in whom laxatives fail to provide adequate relief
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	The association between obesity, aboriginal or indigenous people, indian or alaskan natives living in North America and residence in remote locations and severe outcomes with seasonal and pandemic influenza: a review of the clinical evidence
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Tenofovir disoproxil fumarate (Viread®)
2011	Agenzia sanitaria e sociale regionale, Regione Emilia-Romagna (ASSR)	Criteria for appropriate use of FDG-PET in breast cancer
2011	NIHR Health Technology Assessment programme	Growth monitoring for short stature: update of a systematic review and economic model
2011	Medical Advisory Secretariat (MAS)	Endovascular radiofrequency ablation for varicose veins: an evidence-based analysis
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Preoperative skin antiseptic preparations and application techniques for preventing surgical site infections: a systematic review of the clinical evidence and guidelines
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Histamine dihydrochloride (Ceplene®)
2011	NIHR Health Technology Assessment programme	Processes in recruitment to randomised controlled trials of medicines for children (RECRUIT): a qualitative study
2011	NIHR Health Technology Assessment programme	Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis
2011	Medical Advisory Secretariat (MAS)	Diurnal tension curves for assessing the development or progression of glaucoma: an evidence-based analysis
2011	Medical Advisory Secretariat (MAS)	Constraint induced movement therapy for rehabilitation of arm dysfunction after stroke in adults
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Cetuximab (Erbitux) in combination with oxaliplatin, leucovorin and fluorouracil for colorectal cancer - adjuvant
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Sunitinib (Sutent®)
2011	Andalusian Health Technology Assessment Area (AETSA)	[Guidelines to produce citizen-friendly health technology assessment reports]
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Cetuximab (Erbitux) in combination with capecitabine and cisplatin for advanced or metastatic gastric cancer – first line
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Ferric carboxymaltose (Ferinject®)
2011	NIHR Health Technology Assessment programme	Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day: a systematic review and economic evaluation
2011	NIHR Health Technology Assessment programme	Golimumab for the treatment of psoriatic arthritis
2011	Andalusian Health Technology Assessment Area (AETSA)	[Effectiveness and safety of the HELICA technique in the treatment of endometriosis. Systematic review of the literature]
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Dasatinib (Sprycel) for prostate cancer – in combination with docetaxel
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Valganciclovir (Valcyte®) tablets
2011	Andalusian Health Technology Assessment Area (AETSA)	[Vaccine against Neisseria meningitidis serogroup B]
2011	NIHR Horizon Scanning Centre (NIHR HSC)	EC145 for folate receptor positive ovarian cancer
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Valganciclovir (Valcyte®) powder for oral solution
2011	National Institute for Health and Care Excellence (NICE)	moorLDI2-BI: a laser doppler blood flow imager for burn wound assessment. NICE medical technologies guidance 2
2011	NIHR Health Technology Assessment programme	Evidence Review Group approaches to the critical appraisal of manufacturer submissions for the NICE STA process: a mapping study and thematic analysis
2011	Andalusian Health Technology Assessment Area (AETSA)	[Botulinum toxin A in the treatment of morbid obesity]
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Erlotinib (Tarceva) in combination with sorafenib (Nexavar) for unresectable, advanced or metastatic hepatocellular carcinoma – first line
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Capecitabine (Xeloda®)
2011	The Netherlands Organisation for Health Research and Development (ZonMw)	[Psychological treatment of personality disorders: a multi-centered randomised controlled trial on the (cost-)effectiveness of schema-focused therapy]
2011	Basque Office for Health Technology Assessment (OSTEBA)	[Proposed health survey of the Basque Country for institutionalised population in nursing homes (ESCAV-IR). CAPV 2010]
2011	Andalusian Health Technology Assessment Area (AETSA)	[Effectiveness and safety of percutaneous treatment of pelvic ring fractures]
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Heat-activated liposome encapsulated doxorubicin (ThermoDox) for hepatocellular carcinoma – first line
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Tacrolimus (Advagraf®)
2011	NIHR Health Technology Assessment programme	Development and evaluation by a cluster randomised trial of a psychosocial intervention in children and teenagers experiencing diabetes: the DEPICTED study
2011	Norwegian Knowledge Centre for the Health Services (NOKC)	[Treatment of chronic fatigue syndrome CFS/ME]
2011	Andalusian Health Technology Assessment Area (AETSA)	[Effectiveness and safety of active immunotherapy against telomerase in solid-organ cancer]
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Ipilimumab (Yervoy) for prostate cancer – second line
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Fentanyl (PecFent®)
2011	Agency for Healthcare Research and Quality (AHRQ)	Adjunctive devices for patients with acute coronary syndrome undergoing percutaneous coronary intervention
2011	Haute Autorite de sante (HAS)	[Transcutaneous aortic valve implantation by the transfemoral or transapical route]
2011	NIHR Health Technology Assessment programme	The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review
2011	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Renal denervation in patients with essential hypertonia]
2011	Andalusian Health Technology Assessment Area (AETSA)	[Prioritization of patient decision aids]
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Masitinib with gemcitabine for advanced or metastatic pancreatic cancer
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Darunavir (Prezista®)
2011	Agency for Healthcare Research and Quality (AHRQ)	Effectiveness of early diagnosis, prevention, and treatment of clostridium difficile infection
2011	Scottish Health Technologies Group (SHTG)	What is the clinical and cost effectiveness of the ThinPrep imager® (HologicTM, Inc) for assisted cervical cytology compared with manual reading of liquid based cytology slides?
2011	Haute Autorite de sante (HAS)	[Assessment of glomerular filtration rate and serum creatinine levels in the diagnosis of chronic kidney disease in adults]
2011	NIHR Health Technology Assessment programme	A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-a) inhibitors, adalimumab and infliximab, for Crohn's disease
2011	NIHR Health Technology Assessment programme	The clinical effectiveness and cost-effectiveness of management strategies for sciatica: systematic review and economic model
2011	NIHR Health Technology Assessment programme	Evaluating meta-ethnography: systematic analysis and synthesis of qualitative research
2011	Penn Medicine Center for Evidence-based Practice (CEP)	Tests for early diagnosis of sepsis
2011	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Reorientation of the Austrian parent-child preventive care programme. Part I: Epidemiology - incidence of risk factors and diseases in pregnancy and early childhood]
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Paclitaxel (Paclical) for epithelial ovarian cancer, fallopian tube cancer or peritoneal cancer – second or third line
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Valsartan (Diovan®)
2011	Agency for Healthcare Research and Quality (AHRQ)	Second-generation antidepressants in the pharmacologic treatment of adult depression: an update of the 2007 comparative effectiveness review
2011	Scottish Health Technologies Group (SHTG)	The clinical and cost effectiveness of the use of brachytherapy to treat breast cancer
2011	Haute Autorite de sante (HAS)	[Albumin (or protein) to creatinine ratios in the diagnosis of chronic kidney disease in adults]
2011	Penn Medicine Center for Evidence-based Practice (CEP)	Guidelines for management of sepsis
2011	Belgian Health Care Knowledge Centre (KCE)	Transcatheter aortic valve implantation (TAVI): an updated health technology assessment
2011	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Reorientation of the Austrian parent-child preventive care programme. Part II: international policies, approaches and screening strategies to "normal" and "risk experiences" during pregnancy and early childhood to school entry]
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Caris Target Now™ molecular profiling service for solid malignant tumours
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Filgrastim (Nivestim®)
2011	Agency for Healthcare Research and Quality (AHRQ)	Analgesics for osteoarthritis: an update of the 2006 comparative effectiveness review
2011	Scottish Health Technologies Group (SHTG)	What is the evidence base for the use of orthopaedic spinal surgery for mechanical low back pain or degenerative spondylolisthesis?
2011	Haute Autorite de sante (HAS)	[MRI-guided vacuum-assisted breast biopsy (VABB)]
2011	Penn Medicine Center for Evidence-based Practice (CEP)	Impact of retracted articles on the evidence base for hydroxyethyl starch
2011	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Reorientation of the Austrian parent-child preventive care programme. Part III: Status quo of the financing and cost structures of parent-child services in Austria]
2011	Agency for Healthcare Research and Quality (AHRQ)	Attention deficit hyperactivity disorder: effectiveness of treatment in at-risk preschoolers; long-term effectiveness in all ages; and variability in prevalence, diagnosis, and treatment